IsoPlexis

Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis (www.isoplexis.com), develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The IsoLight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies. IsoPlexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring. IsoPlexis provides a strong level of customer focus. We pride ourselves with a high level of integrity, energy and sense of urgency to “make things happen”.